10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study.
Loretta J. Nastoupil
No relevant relationships to disclose
Sattva Swarup Neelapu
No relevant relationships to disclose
Felipe Samaniego
No relevant relationships to disclose
Fredrick B. Hagemeister
No relevant relationships to disclose
Jorge Enrique Romaguera
No relevant relationships to disclose
Larry W. Kwak
No relevant relationships to disclose
Michael Wang
No relevant relationships to disclose
Luis Fayad
No relevant relationships to disclose
Michelle A. Fanale
No relevant relationships to disclose
Yasuhiro Oki
No relevant relationships to disclose
Jason R. Westin
No relevant relationships to disclose
Maria Alma Rodriguez
No relevant relationships to disclose
Fernando Cabanillas
No relevant relationships to disclose
Peter McLaughlin
No relevant relationships to disclose
Nathan Hale Fowler
Consultant or Advisory Role - Roche/Genentech
Research Funding - Roche/Genentech